1-3 of 3
Kevan Zapolnik
Close
Sort by
Journal Articles

Evaluation of allogeneic and autologous membrane-bound IL-21–expanded NK cells for chronic lymphocytic leukemia therapy

Max Yano, Chia Sharpe, J. Rachel Lance, Janani Ravikrishnan, Kevan Zapolnik, Xiaokui Mo, Jennifer A. Woyach, Deepa Sampath, Adam S. Kittai, Sumithira Vasu, Seema Bhat, Kerry A. Rogers, Dean A. Lee, Natarajan Muthusamy, John C. Byrd
Journal: Blood Advances
Blood Adv (2022) 6 (20): 5641–5654.
https://doi.org/10.1182/bloodadvances.2021005883
Published: 2022
Includes: Supplemental data
Journal Articles

The ROR1 antibody-drug conjugate huXBR1-402-G5-PNU effectively targets ROR1 + leukemia

Eileen Y. Hu, Priscilla Do, Swagata Goswami, Jessica Nunes, Chi-ling Chiang, Sara Elgamal, Ann M. Ventura, Carolyn Cheney, Kevan Zapolnik, Erich Williams, Rajeswaran Mani, Frank Frissora, Xiaokui Mo, Lorenz Waldmeier, Roger R. Beerli, Haiyong Peng, Christoph Rader, Meixiao Long, Ulf Grawunder, John C. Byrd, Natarajan Muthusamy
Journal: Blood Advances
Blood Adv (2021) 5 (16): 3152–3162.
https://doi.org/10.1182/bloodadvances.2020003276
Published: 2021
Includes: Supplemental data
Journal Articles

Par-4 overexpression impedes leukemogenesis in the Eµ-TCL1 leukemia model through downregulation of NF-κB signaling

J. T. Greene, Rajeswaran Mani, Rahul Ramaswamy, Frank Frissora, Max Yano, Kevan Zapolnik, Bonnie Harrington, Ronni Wasmuth, Minh Tran, Xiaokui Mo, Mary McKenna, Vivek M. Rangnekar, John C. Byrd, Subbarao Bondada, Natarajan Muthusamy
Journal: Blood Advances
Blood Adv (2019) 3 (8): 1255–1266.
https://doi.org/10.1182/bloodadvances.2018025973
Published: 2019
Includes: Supplemental data